---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/40670888.md"
description: "China Biologic Products rose by two to three points, with the progress of its innovative drug pipeline providing a floor; Innovent Biologics, Intellia Therapeutics, and 3SBio have basically been flat. The large-cap stocks are stable, with no surprises nor bombs, which is the recent norm for the Hong Kong and U.S. biopharmaceutical leading group."
datetime: "2026-05-12T10:35:09.000Z"
locales:
  - [en](https://longbridge.com/en/topics/40670888.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/40670888.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/40670888.md)
author: "[Dimoo](https://longbridge.com/en/profiles/26968366.md)"
generator: "portal-rs"
---

# China Biologic Products rose by two to three point…


### Related Stocks

- [01177.HK](https://longbridge.com/en/quote/01177.HK.md)
- [01801.HK](https://longbridge.com/en/quote/01801.HK.md)
- [NTLA.US](https://longbridge.com/en/quote/NTLA.US.md)
- [01530.HK](https://longbridge.com/en/quote/01530.HK.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**